Skip to main content
. 2017 Sep 1;109(12):djx098. doi: 10.1093/jnci/djx098

Figure 1.

Figure 1.

Study design schematic limited to participants with questionnaire data (n = 1340). Doxorubicin/cyclophosphamide was received according to one of the following schedules: every two weeks for six cycles, every two weeks for four cycles, or weekly for 15 cycles. Paclitaxel was received every two weeks for six cycles or weekly for 12 cycles. A = doxorubicin; C = cyclophosphamide; T = paclitaxel.